Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.42 |
| ▸ | FASN | P49327 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.41 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | GPR6 | P46095 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.39 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1966796 | 0.79 | ATM (0.49) | ALDH1A1TSHRATMNPC1RAB9A | |
| SCHEMBL1967026 | 0.76 | ATM (0.46) | ALDH1A1TSHRATMNPC1RAB9A | |
| SCHEMBL8430024 | 0.66 | ALDH1A1 (0.56) | ALDH1A1MAPK7FASNNOS1NOS2 | |
| SCHEMBL10243643 | 0.65 | FASN (0.58) | FASN | |
| SCHEMBL27528793 | 0.65 | ALDH1A1 (0.51) | ALDH1A1TSHRATMNPC1RAB9A | |
| SCHEMBL13503971 | 0.64 | GRM5 (0.69) | ALDH1A1TSHRNPC1RAB9ANOS1 | |
| SCHEMBL11923382 | 0.64 | MERTK (0.49) | FASN | |
| SCHEMBL16256936 | 0.64 | KCNA5 (0.59) | ALDH1A1 | |
| SCHEMBL6747493 | 0.64 | ATM (0.65) | ALDH1A1TSHRATMNPC1RAB9A | |
| SCHEMBL16003042 | 0.64 | EPHX2 (0.62) | ALDH1A1FASNNOS1NOS2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846914-B2 | Compositions to effect neuronal growth | NEURALSTEM, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846914-B2 | Compositions to effect neuronal growth | NEURALSTEM, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140147424-A1 | COMPOSITIONS TO EFFECT NEURONAL GROWTH | NEURALSTEM, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140147424-A1 | COMPOSITIONS TO EFFECT NEURONAL GROWTH | NEURALSTEM, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8674098-B2 | Compositions to effect neuronal growth | NEURALSTEM, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8674098-B2 | Compositions to effect neuronal growth | NEURALSTEM, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130195816-A1 | COMPOSITIONS TO EFFECT NEURONAL GROWTH | NEURALSTEM, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130195816-A1 | COMPOSITIONS TO EFFECT NEURONAL GROWTH | NEURALSTEM, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-8362262-B2 | Compositions to effect neuronal growth | NEURALSTEM, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362262-B2 | Compositions to effect neuronal growth | NEURALSTEM, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110135612-A1 | COMPOSITIONS TO EFFECT NEURONAL GROWTH | NEURALSTEM, INC. | 2011-06-09 | — | — | US | disclosed |
| US-20110135612-A1 | COMPOSITIONS TO EFFECT NEURONAL GROWTH | NEURALSTEM, INC. | 2011-06-09 | — | — | US | disclosed |
| US-20110052552-A1 | COMPOSITIONS TO EFFECT NEURONAL GROWTH | NEURALSTEM, INC. | 2011-03-03 | — | — | US | disclosed |
| US-20110052552-A1 | COMPOSITIONS TO EFFECT NEURONAL GROWTH | NEURALSTEM, INC. | 2011-03-03 | — | — | US | disclosed |
| US-7858628-B2 | inhibiting neuronal death, inducing proliferation and differentiation of a neuronal progenitor cell into a neuron and increasing the number of neurons, in humans | NEURALSTEM, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858628-B2 | inhibiting neuronal death, inducing proliferation and differentiation of a neuronal progenitor cell into a neuron and increasing the number of neurons, in humans | NEURALSTEM, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100034784-A1 | inhibiting neuronal death, inducing proliferation and differentiation of a neuronal progenitor cell into a neuron and increasing the number of neurons, in humans | NEURALSTEM, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100034784-A1 | inhibiting neuronal death, inducing proliferation and differentiation of a neuronal progenitor cell into a neuron and increasing the number of neurons, in humans | NEURALSTEM, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7560553-B1 | 1-(Pyrid-4-yl-methyl-),4-((6-piperazino)pyrid-5-yl)-piperazine; proliferation/differentiation of human hippocampal multipotent stem/progenitor cells and neuronal progenitors; drug screening; learning enhancement; cognition activators; Alzheimer's disease; antidepressants; brain trauma; neuroprotectants | NEURALSTEM, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560553-B1 | 1-(Pyrid-4-yl-methyl-),4-((6-piperazino)pyrid-5-yl)-piperazine; proliferation/differentiation of human hippocampal multipotent stem/progenitor cells and neuronal progenitors; drug screening; learning enhancement; cognition activators; Alzheimer's disease; antidepressants; brain trauma; neuroprotectants | NEURALSTEM, INC. (US) | 2009-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100034784-A1 | inhibiting neuronal death, inducing proliferation and differentiation of a neuronal progenitor cell into a neuron and increasing the number of neurons, in humans | DCX, MKI67, INA | ALDH1A1 296/4885TSHR 4417/4885ATM 4119/4885 |
| US-20140147424-A1 | COMPOSITIONS TO EFFECT NEURONAL GROWTH | GAP43, NGF, NEFM | ALDH1A1 3582/4885TSHR 4076/4885ATM 3537/4885 |
| US-20110052552-A1 | COMPOSITIONS TO EFFECT NEURONAL GROWTH | GAP43, NGF, NEFM | ALDH1A1 3834/4885TSHR 3927/4885ATM 3592/4885 |
| US-20110135612-A1 | COMPOSITIONS TO EFFECT NEURONAL GROWTH | GAP43, NGF, NEFM | ALDH1A1 3582/4885TSHR 4076/4885ATM 3537/4885 |
| US-20130195816-A1 | COMPOSITIONS TO EFFECT NEURONAL GROWTH | GAP43, NGF, NEFM | ALDH1A1 3582/4885TSHR 4076/4885ATM 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.